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High-risk mutations in several genes predispose to both colorectal cancer (CRC) and endometrial 
cancer (EC). We therefore hypothesised that some lower-risk genetic variants might also predispose 
to both CRC and EC. Using CRC and EC genome-wide association series, totalling 13,265 cancer 
cases and 40,245 controls, we found that the protective allele [G] at one previously-identified 
CRC polymorphism, rs2736100 near TERT, was associated with EC risk (odds ratio (OR) = 1.08, 
P = 0.000167); this polymorphism influences the risk of several other cancers. A further CRC 
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polymorphism near TERC also showed evidence of association with EC (OR = 0.92; P = 0.03). Overall, 
however, there was no good evidence that the set of CRC polymorphisms was associated with EC 
risk, and neither of two previously-reported EC polymorphisms was associated with CRC risk. A 
combined analysis revealed one genome-wide significant polymorphism, rs3184504, on chromosome 
12q24 (OR = 1.10, P = 7.23 × 10−9) with shared effects on CRC and EC risk. This polymorphism, 
a missense variant in the gene SH2B3, is also associated with haematological and autoimmune 
disorders, suggesting that it influences cancer risk through the immune response. Another 
polymorphism, rs12970291 near gene TSHZ1, was associated with both CRC and EC (OR = 1.26, 
P = 4.82 × 10−8), with the alleles showing opposite effects on the risks of the two cancers.
Colorectal carcinoma (CRC) is the fourth commonest cancer in the western world and cancer of the 
uterine corpus, or endometrial carcinoma (EC), is the fourth commonest cancer among women. Both 
cause significant morbidity and mortality worldwide. There is evidence from rare, Mendelian cancer 
predisposition syndromes that CRC and EC can have a common aetiology. Specifically, germline muta-
tions in mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS21, and in DNA polymerases 
POLD1 and POLE2 predispose to a high incidence (lifetime risk 30–71%2–5) of both CRC and EC. The 
MMR system maintains genomic stability by correcting mismatched nucleotide pairs that arise during 
DNA replication and MMR mutations cause a microsatellite instability (MSI+ ) phenotype in CRCs and 
ECs6. Bi-allelic MLH1 promoter methylation7,8 and a few somatic mutations in MLH1 and MSH29 are 
seen in sporadic CRCs and ECs, causing the same MSI+ and hypermutator phenotype. Histologically, 
MMR-deficient CRCs and ECs are characterised by poor differentiation and the presence of mucinous 
and signet-cell features and tumour-infiltrating lymphocytes10,11. POLE and POLD1 encode polymerases 
that synthesise respectively the leading and lagging strand of the DNA replication fork. The exonuclease 
(proofreading) domains of these polymerases increase replication fidelity by recognising and excising 
mispaired bases12,13. Germline missense mutations in the exonuclease domains of POLD1 and POLE 
predispose to both CRC and EC, and somatic POLE mutations occur in sporadic CRCs and ECs2,14–16. 
Polymerase exonuclease domain mutations (EDMs) do not cause MSI, but lead to an ultramutator phe-
notype, with over one million base substitutions in some cancers.
Genome-wide association studies (GWAS) have successfully identified tens of common single nucle-
otide polymorphisms (SNPs) associated with a modestly increased risk (typically 10–25%) of CRC. In 
addition, one EC SNP, near HNF1B, has been reported at stringent levels of statistical significance. To 
date, the lists of CRC and EC SNPs are non-overlapping. Since CRC and EC may share mechanisms of 
pathogenesis, as evidenced by the high-penetrance germline mutations and the somatic (epi)mutations 
discussed above, we hypothesised (i) that some CRC SNPs may predispose to EC, and vice versa, and 
(ii) that there exist unidentified SNPs that predispose to both CRC and EC. In this study, we tested these 
hypotheses using 16 different CRC and EC GWAS data sets, totalling 13,265 cancer cases and 40,245 
cancer-free or population controls.
Methods
GWAS data sets. Five CRC GWAS data sets genotyped on various Illumina tag-SNP arrays were 
available, comprising: (i) CORGI (UK1), (ii) Scotland 1, (iii) VICTOR/QUASAR2/BC58, (iv) CFR1 and 
(v) CFR2/CGEMS (total 5,725 cases and 6,671 controls)17–21. The VQ58, CORGI and Scotland 1 series 
were genotyped using Illumina Hap300, Hap240S, Hap370, Hap550 or Omni2.5M arrays. BC58 gen-
otyping was performed as part of the WTCCC2 study on Hap1.2M-Duo Custom arrays. The CCFR 
samples were genotyped using Illumina Hap1M, Hap1M-Duo or Omni-express arrays. CGEMS samples 
(all controls) were genotyped using Illumina Hap300 and Hap240 or Hap550 arrays. Standard quality 
-control measures were applied as reported17. Moreover, any duplicate or cryptically related samples were 
excluded by pairwise identity by descent (IBD) analysis.
EC GWAS comprised: (i) NSECG, (ii) ANECS and (iii) SEARCH (total 2,212 cases and 6,725 con-
trols)22. All samples were of European ancestry with the majority of samples from the UK, and others 
from USA and Australia. Standard quality control measures were performed for each GWAS, as described 
in the referenced publications, and details about each dataset are shown in Table 1. Some of the control 
datasets, including the Wellcome Trust Case Control Consortium 2 (WTCCC2)23, have previously been 
used in both CRC and EC GWAS. We ensured that such controls were assigned proportionately to case 
data sets and were not used more than once (Table 1).
Principal component analysis (PCA) was conducted for all samples together, to ensure that all indi-
viduals were of European ancestry and we excluded all individuals who clustered outside the main cen-
troid in pairwise plots of the first 4 PCs. The adequacy of case-control matching and possibility of 
differential genotyping of cases and controls was assessed using Q-Q plots of test statistics. λ GC values 
for the CORGI, Scotland1, VQ58, CCFR1 and CCFR2 studies were 1.02, 1.01, 1.01, 1.02 and 1.03 respec-
tively, and those for NSECG, ANECS and SEARCH were 1.02, 1.02 and 1.00 respectively.
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Study Case sampling frame Control sampling frame Genotyping Platform Cases Controls
CRC GWAS
1 UK1-CORGI Colorectal Tumour Gene Identifica-tion Consortium
England; Genetics clinic-based, 
with family history of CRC
England; spouses and partners of cases 
with no personal or family history of 
colorectal neoplasia
Illumina Hap550 888 899
2 Scotland1 Scotland Scotland; population based CRC cases, age < 55
Scotland; from NHS registers matched by 
age and region
Illumina HumanHap300 
and Illumina Human-
Hap240S
973 998
3 VQ VICTOR/QUASAR2
UK; CRC cases enrolled in 
chemotherapy clinical trials 
(NSAID and monoclonal 
antibody)
Illumina HumanHap300, 
Illumina HumanHap270, 
Illumina Human 
1.2MDuo
1894 2674
WTCCC2 
BC58 UK 1958 Birth Cohort
UK; population based controls, born 
within one week in 1958 Illumina 1.2M
4 CFR1 Colon Cancer Family Registry Phase1
USA and Australia; cases from 
cancer registries
USA and Australia; population based 
controls, no family history Illumina Human1M 1175 999
5 CFR2 Colon Cancer Family Registry Phase 2
USA and Australia; cases from 
cancer registries Illumina Human1M 795
CGEMS 
prostate
Cancer Genetic Markers of Suscep-
tibility (Prostate)
USA; population based cancer free con-
trols from prostate study Illumina HumanHap550 1101
 EC GWAS
6 NSECG National Study of Endometrial Cancer Genetics UK; population based cases
Illumina660WQuads, 
HumanHap550 925
 CGEMS breast
Cancer Genetic Markers of Suscep-
tibility (Breast)
USA; population based cancer free con-
trols from breast study Illumina HumanHap550 1141
7 ANECS Australian National Endometrial Cancer Study
Australia; population based 
cases Illumina 610K 606
QIMR Queensland Institute of Medical Research
Australia; parents of participants in 
adolescent twin study Illumina 610K 1846
HCS Hunter Community Study Australia; population-based cohort Illumina 610K 1237
8 SEARCH UK Studies of Epidemiology and Risk factors in Cancer Heredity
England; population based 
cases via cancer registries, 
age < 69
Illumina 610K 681
WTCCC2 
NBS
UK; population based controls identified 
through National Blood Service Illumina 1.2M 2501
 EC COGS
9 ANECS Australian National Endometrial Cancer Study
Australia; population based 
cases Illumina Infinium iSelect 373
NECS Newcastle Endometrial Cancer Study Australia; hospital-based cases Illumina Infinium iSelect 165
ABCFS Australian Breast Cancer Family Study Australia; from electoral rolls Illumina Infinium iSelect 443
AOCS Australian Ovarian Cancer Study Australia; population-based, from elec-toral rolls Illumina Infinium iSelect 817
MCCS Melbourne Collaborative Cohort Study
Australia; random sample from initial 
cohort Illumina Infinium iSelect 437
10 SEARCH UK Studies of Epidemiology and Risk factors in Cancer Heredity
England; population based 
cases England; population based controls Illumina Infinium iSelect 773 7,510
11 NSECG National Study of Endometrial Cancer Genetics
England; population based 
cases Illumina Infinium iSelect 965
BBCS British Breast Cancer Study
UK; friend, sister-in-law, daughter-in-law 
or other  
non-blood relative of breast cancer case
Illumina Infinium iSelect 1,353
SBCS Sheffield Breast Cancer Study
UK; women attending Sheffield Mam-
mography Screening, with no breast 
lesion
Illumina Infinium iSelect 835
UKBGS UK Breakthrough Generations Study
UK; women without breast lesions select-
ed from BGS cohort Illumina Infinium iSelect 449
12 MECS Mayo Endometrial Cancer Study USA; Hospital based cases Illumina Infinium iSelect 221
MCBCS Mayo Clinic Breast Cancer Study USA; Cancer-free women presenting for general medical examination Illumina Infinium iSelect 1,762
MCBCS/
MCOCCCS
Mayo Clinic Ovarian Cancer 
Case-Control Study
USA; Cancer-free women presenting for 
general medical examination Illumina Infinium iSelect 593
13 LES Leuven Endometrial Cancer Study Belgium; hospital based cases Illumina Infinium iSelect 321
Continued
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EC targeted genotyping data sets. A further 4,330 EC cases and 26,849 female controls were gen-
otyped as part of the Endometrial Cancer Association Consortium (ECAC), with samples from seven 
countries: UK, USA, Belgium, Germany, Norway, Sweden and Australia. The controls were selected from 
healthy females participating in the Breast Cancer Association Consortium (BCAC) and Ovarian Cancer 
Association Consortium (OCAC) part of the iCOGS project and matched and analysed with cases in 
eight groups by geographical location (see Table  1). These samples were genotyped using a custom 
Illumina Infinium iSelect array with 211,155 SNPs designed by the COGS (Collaborative Oncological 
Gene-environment Study) initiative24–27. The SNPs on this array were chosen based on regions of interest 
from previous breast, prostate, ovarian and endometrial cancer studies, rather than on genome-wide 
coverage. We did not impute genotypes from the COGS studies, but included directly-genotyped SNPs 
in the discovery meta-analysis. These SNPs were not used for locus fine mapping.
Association study and meta-analysis. Whole-genome imputation using two reference panels (1000 
Genomes 2012 release28 and 196 high-coverage whole genome-sequenced UK individuals) was performed 
with IMPUTE229, yielding up to 6 million SNPs either typed or imputed with high quality (info score 
> 0.9). Case-control analysis for each GWAS data set was performed using frequentist tests with a logistic 
regression model using SNPTEST (v2.4)30. There was no evidence of systematic over-dispersion of the 
test statistic for any of the 16 studies (lambdaGC = 1.01–1.04 based on weakly correlated SNPs, r2 < 0.2). 
Fixed-effects, inverse variance weighted meta-analysis was conducted for the 6 million well-imputed 
SNPs in the eight CRC and EC GWAS (8,935 cases, 13,396 controls) across the genome using GWAMA 
(v2.1)31. For the ~200,00 SNPs genotyped on the COGS array, the additional 4,330 EC cases and 26,849 
controls from ECAC were included in a meta-analysis of 16 studies yielding a total of 13,265 cases and 
40,245 controls for these loci. SNPs with globally significant CRC/EC associations (Pmeta < 5 × 10−8) were 
identified and the regions examined using standard fine mapping and annotation methods.
Previously reported CRC and EC SNPs. The effects of 25 previously published tag-SNPs that have 
been formally associated with CRC risk in GWAS were investigated in EC (Table  2). We additionally 
assessed two SNPs (near TERT32 and MTHFR33,34) with convincing CRC associations from focussed stud-
ies. We estimated that our EC sample set provided 72% power to detect the effect of a typical CRC SNP 
(allele frequency = 0.25, per allele odds ratio = 1.1) at P = 0.05, and 23% power to detect a similar allele at 
P = 0.001, corresponding to a false discovery rate of q = 0.05 in our sample. Two EC SNPs from GWAS22 
Study Case sampling frame Control sampling frame Genotyping Platform Cases Controls
LMBC Leuven Multidisciplinary Breast Centre Belgium; controls from blood donors Illumina Infinium iSelect 1,382
14 BECS/HJECS Bavarian/Hannover-Jena Endome-trial Cancer Study
Germany; population and 
hospital-based cases Illumina Infinium iSelect 137
BBCC Bavarian Breast Cancer Cases and Controls
Germany; healthy women > 55yrs from 
newspaper advertisement Illumina Infinium iSelect 441
BSUCH Breast Cancer Study of the Univer-sity Clinic Heidelberg Germany; female blood donors Illumina Infinium iSelect 920
ESTHER ESTHER Breast Cancer Study Germany; random sample from routine health check-up Illumina Infinium iSelect 486
GC-HBOC German Consortium for Hereditary Breast & Ovarian Cancer Germany; KORA study Illumina Infinium iSelect 138
GENICA Gene Environment Interaction and Breast Cancer in Germany Germany; random address sample Illumina Infinium iSelect 420
MARIE Mammary Carcinoma Risk Factor Investigation
Germany; randomly drawn from popula-
tion registries Illumina Infinium iSelect 1,712
15 MoMaTEC Molecular Markers in Treatment of Endometrial Cancer
Norway; population based 
cases Illumina Infinium iSelect 599
NBCS Norwegian Breast Cancer Study Norway; attendees at Norwegian Breast Cancer Screening Program Illumina Infinium iSelect 234
16 CAHRES/RENDOCAS
Cancer Hormone Replacement 
Epidemiology
Sweden; population based 
cases Illumina Infinium iSelect 543
RENDOCAS Registry of Endometrial Cancer in Sweden Sweden; hospital based cases Illumina Infinium iSelect 233
KARBAC Karolinska Breast Cancer Study Sweden; blood donors Illumina Infinium iSelect 6,917
pKARMA
Karolinska Mammography Project 
for Risk Prediction of Breast 
Cancer
Sweden; cancer-free participants of mam-
mography screening Illumina Infinium iSelect 6,917
Table 1.  Details of the CRC and EC studies used in this analysis.
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Cancer 
GWAS SNP Chr
Position 
(build 37)
Nearby 
gene(s)
Minor 
Allele MAF
P-value 
in other 
phenotype
OR 
(minor 
allele) L95 CI U95 CI
Same 
effect 
direction 
in CRC 
and EC?
iCOGS 
EC 
samples 
included? Reference
CRC rs1801133 1 11,856,378 MTHFR A 0.34 0.686 0.99 0.92 1.06 Yes No Hubner et al. Int Journal Cancer2006
CRC rs10911251 1 183,081,194 LAMC1 C 0.43 0.236 1.04 0.97 1.12 No No
Peters et al. Gastroenterology 
2013, Whiffin et al. Hum Mol 
Genet 2014
CRC rs6691170 1 222,045,446 DUSP10 T 0.37 0.023 1.09 1.01 1.17 Yes No Houlston et al. Nat Gen 2010
CRC rs10936599 3 169,492,101 TERC T 0.24 0.033 0.92 0.84 0.99 Yes No Houlston et al. Nat Gen 2010
CRC rs2736100 5 1,286,516 TERT A 0.5 0.000167 0.93 0.89 0.96 No Yes
Kinnersley Br J Cancer 2012, 
Rafnar et al. Nat Gen 2009 
Peters et al. Human Genetics 
2012
CRC rs647161 5 134,499,092 PITX1 C 0.33 0.559 1.02 0.95 1.1 No No Jia et al. Nat Gen 2013, Whiffin et al. Hum Mol Genet 2014
CRC rs1321311 6 36,622,900 CDKN1A A 0.24 0.925 1.00 0.92 1.08 No No Dunlop et al. Nat Gen 2012
CRC rs16892766 8 117,630,683 EIF3H C 0.09 0.134 0.95 0.88 1.02 No Yes Tomlinson et al. Nat Gen 2008
CRC rs6983267 8 128,413,305 MYC T 0.46 0.143 1.03 0.99 1.07 No Yes Tomlinson et al. Nat Gen 2007
CRC rs10795668 10 8,701,219 GATA3 A 0.32 0.715 0.99 0.92 1.06 Yes No Tomlinson et al. Nat Gen 2008
CRC rs1035209 10 101,345,366 NKX2-3, SLC25A28 T 0.2 0.243 1.05 0.97 1.15 Yes No
Whiffin et al. Hum Mol Genet 
2014
CRC rs3824999 11 74,345,550 POLD3 T 0.49 0.647 0.98 0.92 1.05 Yes No Dunlop et al. Nat Gen 2012
CRC rs3802842 11 111,171,709
COLCA1, 
COLCA2, 
POU2AF1
C 0.31 0.513 0.99 0.94 1.03 No Yes Tenesa et al. Nat Gen 2008
CRC rs10774214 12 4,368,352 CCND2 T 0.38 0.171 1.05 0.98 1.13 Yes Yes Jia et al. Nat Gen 2013, Whiffin et al. Hum Mol Genet 2014
CRC rs3217810 12 4,388,271 CCND2 T 0.14 0.762 1.02 0.92 1.13 Yes No
Peters et al. Gastroenterology 
2013, Whiffin et al. Hum Mol 
Genet 2014
CRC rs11169552 12 51,155,663 DIP2B, ATF1 T 0.26 0.963 1.00 0.93 1.08 No No Houlston et al. Nat Gen 2010
CRC rs4444235 14 54,410,919 BMP4 C 0.48 0.1 1.03 0.99 1.07 Yes Yes Houlston et al. Nat Gen 2008
CRC rs1957636 14 54,560,018 BMP4 T 0.41 0.961 1.00 0.96 1.04 No Yes Tomlinson et al. PLoS Genetics 2011
CRC rs16969681 15 32,993,111 GREM1 T 0.09 0.379 0.97 0.90 1.04 No Yes Tomlinson et al. PLoS Genetics 2011
CRC rs11632715 15 33,004,247 GREM1 A 0.48 0.332 1.04 0.97 1.11 Yes No Tomlinson et al. PLoS Genetics 2011
CRC rs9929218 16 68,820,946 CDH1, CDH3 A 0.29 0.679 0.98 0.91 1.06 Yes No Houlston et al. Nat Gen 2008
CRC rs4939827 18 46,453,463 SMAD7 C 0.46 0.229 0.98 0.94 1.02 Yes Yes Broderick et al. Nat Gen 2007
CRC rs10411210 19 33,532,300 RHPN2 T 0.09 0.202 1.04 0.98 1.12 No Yes Houlston et al. Nat Gen 2008
CRC rs961253 20 6,404,281 BMP2 A 0.37 0.975 1.00 0.96 1.04 No Yes Houlston et al. Nat Gen 2008
CRC rs4813802 20 6,699,595 BMP2 G 0.37 0.268 1.04 0.97 1.12 Yes No Tomlinson et al. PLoS Genetics 2011
CRC rs2423279 20 7,812,350 HAO1 C 0.24 0.897 1.01 0.93 1.09 Yes No Jia et al. Nat Gen 2013, Whiffin et al. Hum Mol Genet 2014
CRC rs4925386 20 60,921,044 LAMA5 T 0.3 0.064 1.07 1.00 1.16 No No
Houlston et al. Nat Gen 2010, 
Peters et al. Human Genetics 
2012
EC rs749292* 15 51,558,731 CYP19A1 A 0.46 0.066 0.95 0.91 1.00 No Yes Spurdle et al. Nat Gen 2011
EC rs4430796* 17 36,098,040 HNF1B G 0.47 0.601 0.99 0.94 1.04 Yes Yes Setiawan et al. Cancer Epidemi-ol Biomarkers Prev 2009
Table 2.  Association statistics for the known CRC SNPs tested in EC, and vice versa. 
Chr = chromosome, OR = odds ratio, MAF = minor allele frequency, OR = odds ratio, L95 CI = lower 95% 
confidence interval odds ratio, U95 CI = upper 95% confidence interval odds ratio. The original studies 
providing the data are listed in Supplementary Information.
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were similarly investigated in CRC. All of these SNPs were either discovered or replicated in European 
populations and were genotyped directly or had near-perfect proxies on the Illumina GWAS arrays used; 
13 of the SNPs were also present on the iCOGS arrays. Three EC SNPs in the TERT-CLPTM1L region35 
were not included in this analysis, owing to poor tagging on the GWAS arrays and hence sub-optimal 
imputation.
Genome-wide enrichment of susceptibility SNPs between CRC and EC. Beyond the 29 pre-
viously published associations, we investigated the presence of genome-wide enrichment for CRC and 
EC. After removing previous associations, we pruned the set of 6 million typed or well-imputed SNPs 
(r2 < 0.1) to 246,896. Using several P value thresholds, we determined whether there was a tendency for 
the same SNPs to co-occur in the lists of putative CRC and EC SNPs, irrespective of direction of effect.
Results
We initially investigated the 29 previously-identified CRC and EC polymorphisms (Table 2). One SNP, 
rs2736100, originally reported in CRC32, was significantly associated with EC risk (OR: 0.93, 95% con-
fidence interval (95% CI): 0.89-0.96, P = 0.000167) after correcting for multiple testing (P< 0.001). The 
risk allele for CRC [A] was protective in EC. rs2736100 lies in the intronic region of the telomerase 
reverse transcriptase TERT. It or highly correlated SNPs have previously been associated with the risk of 
multiple different cancer types, and we ourselves have previously found evidence that these TERT SNPs 
are associated with EC risk35. Two other CRC SNPs (rs6691170 and rs10936599) were nominally associ-
ated with EC risk (P < 0.05). Interestingly, the latter of these lies close to the telomerase RNA component 
TERC locus; it is a multi-cancer risk SNP36–38 and has been associated with longer telomeres. Overall, 
15 of the 29 SNPs showed the same direction of effect in both cancer types (that is, same nominal risk 
allele, irrespective of effect size), and this evidently was not a significant deviation from randomness 
(P = 1, binomial sign test).
Meta-analysis of all CRC and EC data sets revealed a single genome-wide significant SNP, rs3184504, 
on chromosome 12q24 (OR: 1.10, 95% CI 1.07–1.13, Pmeta: 7.23 × 10−9, heterogeneity I2 = 0; Fig.  1, 
Supplementary Table 1). This SNP is a missense variant (p.Trp262Arg) in exon 4 of SH2B3. It has not 
previously been associated with either CRC or EC. The major [C] allele was consistently the risk allele 
in all datasets, including those analysed using the iCOGS array, on which the SNP was included due to 
promising, but unproven, associations below genome-wide significance in previous breast cancer and EC 
GWAS. An additional 3 SNPs (Fig.  2) in strong pairwise linkage disequilibrium (LD) with rs3184504 
(r2 > 0.9) showed strong evidence of CRC-EC association (Pfine mapping < 10−5). These 4 SNPs lie in a 
68kb region, that includes the genes SH2B3 and ATXN2, and their functional annotation is shown in 
Supplementary Table 2. None of the 4 SNPs was associated with the mRNA level of SH2B3, ATXN2 or 
other nearby genes in public eQTL databases (details not shown).
There are SNPs that have previously been independently identified in GWAS of different phenotypes 
where the risk allele for one phenotype is the protective allele for another39,40. In order to search for SNPs 
for which the same allele has differing directions of effect in CRC and EC, we conducted a fixed-effect 
Figure 1. Forest plot showing association between cancer risk and rs3184504 genotype in each data set. 
Studies are shown in order of EC GWAS, EC iCOGS and CRC GWAS (Table 1). Black squares represent the 
point estimate of the odds ratio and have areas proportional to study size. Lines represent 95% confidence 
intervals. The diamond shows the summary statistic. The overall heterogeneity statistic is shown. There is 
also no evidence of heterogeneity between the pooled CRC and pooled EC studies (details not shown).
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meta-analysis with the odds ratios of all the CRC SNPs GWAS inverted (Supplementary Table 3). In 
this analysis, we discovered rs12970291 on chromosome 18q22, where the major G allele is protective 
in CRC (OR:0.78, 95%CI:0.69-0.90, 3.42 × 10−4) and confers risk in EC (OR:1.24, 95%CI: 1.11–1.38, 
p:1.11 × 10−4). In meta-analysis, the rs12970291 association reached genome-wide significance (OR:1.26, 
95%CI:1.16–1.38, Pmeta:4.82 × 10−8; Fig. 3). Fine mapping analysis identified a large number of SNPs in 
high pairwise LD with rs12970291 (r2 > 0.85), in a 70 kb region that includes the gene TSHZ1, which 
is ~15 kb proximal to rs12970291 (Fig.  4). Seventeen SNPs had a stronger disease association than 
rs12970291 in fine mapping, with the lowest P value at rs35185115 (Pfine mapping = 1.08 × 10−6). Fine map-
ping of CRC and EC GWAS separately (Supplementary Figure 1) showed an association peak occurring 
in the same LD block between 10.5–51.8 kb downstream of TSHZ1, while an additional suggestive asso-
ciation signal near rs17263435 (PEC = 4.35 × 10−5) was not present in CRC (PCRC = 0.1). Several SNPs in 
the region have potential functional importance (Supplementary Table 4), and of particular note is the 
missense SNP rs3390274 (p.Ala468Thr) in the last exon of TSHZ1. SNPs with a pairwise LD of > 0.4 with 
rs12970291 in the region were not significantly associated with mRNA level of TSHZ1 or other nearby 
genes in public eQTL databases (details not shown).
Figure 2. Regional association plot for region around rs3184504. Plots are produced in LocusZoom 
and show the most strongly associated SNP, rs3184504 (purple diamond). rs7137828, intron of ATXN2, is 
the SNP with the second lowest P value. The primary aim of this analysis is to compare association signals 
among SNPs in the region. Therefore, the data are derived from a meta-analysis of genotyped or high-quality 
imputed SNPs in the GWAS data sets, and because imputation quality was more variable in iCOGS than in 
the GWAS data, the iCOGS samples are not included.
Figure 3. Forest plot showing association between cancer risk and rs12970291 genotype in each data set. 
Legend is as for Fig. 1.
www.nature.com/scientificreports/
9Scientific RepoRts | 5:17369 | DOI: 10.1038/srep17369
Finally, we performed genome-wide enrichment analysis for nearly 250,000 independent SNPs 
(r2 < 0.1) below genome-wide significance levels to investigate whether there was a set of cryptic shared 
CRC and EC risk loci (Supplementary Table 5). Using P value thresholds of 10−3, 10−2 and 0.05, we found 
no evidence of a significant sharing of CRC and EC SNPs using this method.
Discussion
Using a combined CRC and EC GWAS meta-analysis, we have identified a region on chromosome 12q24.1 
spanning two genes, SH2B3 and ATXN2, which contains a SNP that is formally associated at GWAS 
thresholds of significance with cancer risk. Of the variants in this region, rs3184504 is of particular interest, 
because it is a non-synonymous change (TGG → CGG; p.Trp262Arg) in the pleckstrin homology domain 
of SH2B3, which is a priori a much stronger candidate than the spinocerebellar ataxia gene ATXN2. SH2B3 
is a member of the SH2B adaptor family of proteins and is involved in a range of signalling activities by 
growth factor and cytokine receptors. It is a key negative regulator in cytokine signalling in haemato-
poiesis, and is expressed at a high level in the bone marrow and white blood cells, but at a low level in 
the normal bowel and endometrium (EMBL-EBI expression atlas). Comparative genomics shows that the 
rs3184504 risk allele (C, Arg residue) is conserved in all primates and some vertebrates (Supplementary 
Figure 1), and has a much lower allele frequency (~0.5) in Europeans than in African, Asian and admixed 
American populations (~1.0). Amino acids Trp (tryptophan) and Arg (arginine) present in the two 
forms of the polymorphic SH2B3 protein possess a hydrophobic (uncharged) and positively charged side 
chain respectively. Different programs that predict the effect of this variation on protein function vary in 
their assessment (Grantham score = 121 (range 0–215)41, Polyphen2 = 0.1242, SIFT = 1.043, CADD score 
PHRED-scaled = 5.53244); overall, the possibility remains that the amino acid change has a modest or 
greater effect on protein function. The NHGRI GWAS Catalog shows that SNPs in the SH2B3/ATNX2 
region including rs3184504 and rs653178 have been previously associated with immune-mediated con-
ditions: coeliac disease45, rheumatoid arthritis43, type 1 diabetes46, autoimmune hepatitis47 and also car-
diovascular traits including coronary artery disease48 and blood pressure49. The genotype at rs653178 has 
been linked to levels of SH2B3 mRNA expression in peripheral blood cell eQTL analysis (p = 9.24 × 10−12), 
although this association is not present in public eQTL data sets. Interestingly, rs3184504 T is generally the 
risk allele in autoimmune traits, suggesting opposing effects of the functional polymorphism on cancer and 
other traits, perhaps via shared effects on immune activation. A similar phenomenon has been found for 
the HNF1B SNP rs4430796 which has opposing effects on EC and type 2 diabetes risk50.
The TERT-CLPTM1L locus has been identified in multiple cancer susceptibility GWAS51–58 and it is 
of interest that the CRC SNP rs2736100 also shows signs of significance in EC in our analysis (OR:1.08, 
95%CI:1.04-1.12, P = 1.67 × 10−4). In parallel with this study and using overlapping data sets, we have 
recently performed a detailed analysis of the TERT-CLPTM1L locus in EC which provided evidence that 
rs7705526 is associated with EC risk (Passoc = 7.7 × 10−5), albeit at locus-specific rather than genome-wide 
Figure 4. Regional association plot for region around rs12970291. Legend is as for Fig. 2, except as 
follows. The most strongly associated SNP from the full discovery meta-analysis (rs12970291, purple 
diamond) is not the most strongly associated in the GWAS data sets. The most strongly associated SNP, 
rs35185115, lies about 30kb downstream of TSHZ1, but this SNP imputed poorly in iCOGS and was 
therefore assessed in fewer samples in the discovery meta-analysis than rs12970291, which was directly 
genotyped in iCOGS.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 5:17369 | DOI: 10.1038/srep17369
significance thresholds35. rs7705526 is moderately correlated with rs2736100 (r2 ~ 0.5) but is poorly tagged 
in most Illumina GWAS arrays. Supplementary Figure 2 shows the complex LD structure between these 
two SNPs and 4 other SNPs previously associated with CRC and EC at varying levels of significance 
(P = 8.4 × 10−3 to 4.9 × 10−6) at this locus.
The rs2736100 A allele is the risk allele for CRC and testicular germ cell tumour, while the same allele 
is protective for EC, glioma and lung cancer, suggesting that this variant has its effects in a tissue-specific 
manner. Interestingly, we have found evidence in this study for a SNP (rs12970291, chromosome 18q22) 
that has opposing allelic effects on CRC and EC risk. The top candidate gene in this region is TSHZ1 
which encodes zinc finger homeodomain factor teashirt zinc finger family member 1, a protein involved 
in skin, skeletal, brain and gut development59 that is functionally related to the CRC gene BMP460. One 
of several candidate SNPs near and within TSHZ1 is the uncommon missense variant rs33930274 (p.Al-
a468Thr) in the last exon of TSHZ1, although the predicted functional consequences of this change are 
inconsistent (Grantham score = 58, SIFT = 0.0, Polyphen2 = 0.0, CADD score PHRED-scaled: 0.001).
Apart from the SH2B3 and TERT SNPs, only two of 27 previously-reported CRC SNPs, including one 
near TERC, showed any good evidence of association with EC and neither of the known EC SNPs was 
associated with CRC risk. Otherwise, there was no convincing evidence for a shared EC and CRC predis-
position based on common polymorphisms, although it will be important to keep repeating multi-cancer 
GWAS as more risk SNPs are identified, and sub-set analyses – for example of MSI+ ECs and CRCs – 
might also be fruitful. It remains a little puzzling that, like breast and ovarian cancer, CRC and EC share 
high-penetrance risk alleles, yet relatively few common risk alleles of modest effect.
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